

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor’s Choice

New Programs

GIGAVPCOXT, GIGAVPFOXT: Pembrolizumab and Trastuzumab in Combination with Fluoropyrimidine and Oxaliplatin for Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma

SMNAPEM: Pembrolizumab for Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma

Cancer Drug Manual®

New: calaspargase pegol, capivasertib, datopotamab deruxtecan

Revised: carboplatin, olaparib, thiotepa, trastuzumab emtansine

Chemotherapy Preparation and Stability Chart:

doxorubicin pegylated liposomal, thiotepa, topotecan

Editorial Board Changes

Community Oncology Network

Terrace CON Clinic – New Facility, New Name

Benefit Drug List

New: GIGAVPCOXT, GIGAVPFOXT, SMNAPEM

Deleted: LYCARTOP, LYCTCLBV

NEW Protocols, PPPOs and Patient Handouts

GI GIGAVPCOXT, GIGAVPFOXT **SM** SMNAPEM

REVISED Protocols, PPPOs and Patient Handouts

CN CNCARV, CNELTZRT **GI** GIAAVCT, GIGAVFFOXT, GIRCRT **GO** GOENDAVPL **HN** HNLAALTPRT, HNLACETRT, HNLAPRT, HNNLAPRT **LY** HLHETCSPA, LYABVD, LYACAL, LYALEM, LYALIT, LYASPMEDX, LYAVDBV, LYBEND, LYCDA, LYCHLOR, LYCHOP, LYCHOPO, LYCHOPR, LYCHOPRMTX, LYCHPBV, LYCLLBEND, LYCSPA, LYCVP, LYCVPPABO, LYCYCLO, LYDARCBDF, LYFACAL, LYFIBRU, LYFLU, LYGDP, LYGEMOXPEG, LYGVLD, LYHDMRTEM, LYHDMTXPRO, LYIBRU, LYIT, LYIVACR, LYMBEX, LYMFECF, LYMIBRU, LYNIV, LYNIV4, LYPALL, LYPEM, LYPEM6, LYPRA, LYRICE, ULYROMI, LYSILTUX, LYSMILE, LYVENOB, LYVIPDRT **MY** MYBLDF, MYBLDPRE, MYBORMTN, MYBORPRE, MYBORREL, MYBSD, MYCARDEX, MYCARLD, MYDARBD, MYDARCBDF, MYDARLD, MYDARLDF, MYHDC, UMYISACARD, UMYISAPOMD, UMYLDF, MYLDREL, MYLENMTN, MYMP, MYMPBOR, UMYPOMDEX **PU** PUCAT **SA** SATEMBEV **SM** SMMCCAVE

Resources and Contact Information

Editor’s Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 December 2024. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Gastrointestinal

Pembrolizumab and Trastuzumab in Combination with Fluoropyrimidine and Oxaliplatin for Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma (GIGAVPCOXT, GIGAVPFOXT) – The BC Cancer Gastrointestinal Tumour Group is adding pembrolizumab to trastuzumab plus fluoropyrimidine and oxaliplatin chemotherapy for the treatment of patients with HER2-positive metastatic or inoperable locally advanced gastric, gastroesophageal junction or esophageal adenocarcinoma. Treatment eligibility includes PD-L1 expression with combined positive score (CPS) ≥ 1 and no prior treatment in the advanced

New Programs

setting.¹ Patients currently on treatment with GIGAVCOXT/GIGAVFFOXT without progression may switch to GIGAVPCOXT/GIGAVPFOXT (i.e., addition of pembrolizumab) if all other eligibility criteria are met.

Approval of this new treatment program is based on the phase III randomized, controlled KEYNOTE-811 trial.² Patients were randomized to pembrolizumab or placebo, combined with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy. Progression-free survival and median overall survival were significantly improved in the pembrolizumab group, specifically in patients whose tumours express PD-L1 CPS ≥ 1 . Treatment was associated with toxicities consistent with the known safety profiles of the agents.

Skin & Melanoma

Pembrolizumab for Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma (SMNAPEM) – The BC Cancer Skin and Melanoma Tumour Group is implementing neoadjuvant pembrolizumab for patients presenting with stage IIIB to IV M1c resectable melanoma. Currently this patient population receives one year of adjuvant anti-PD-1 therapy after complete resection (or combination dabrafenib/trametinib if the tumour has a BRAF V600 mutation). In the new treatment program, patients with resectable stage IIIB to IV M1c melanoma may receive three cycles of pembrolizumab preoperatively, followed by the remaining pembrolizumab cycles after surgery. In addition to checking morning serum cortisol prior to the first three cycles, it must also be checked prior to surgery to identify potential adrenal insufficiency. Three-weekly dosing must be used during the pre-operative neoadjuvant phase, however, patients may be switched from 3-weekly to 6-weekly dosing in the post-operative adjuvant phase without requiring CAP approval. Both neoadjuvant-adjuvant pembrolizumab, and the adjuvant treatment programs (SMAJNIV, SMAJNIV4, SMAJPEM, SMAJPEM6), will provide the same overall duration of anti-PD-1 therapy.

Approval of this treatment program is supported by evidence from the phase II, open-label, randomized SWOG S1801 trial.^{3,4} Patients with stage IIIB to IV M1c melanoma were randomized to three doses of neoadjuvant pembrolizumab, followed by surgery, and 15 further doses of 3-weekly pembrolizumab (neoadjuvant-adjuvant group), or to surgery followed by 3-weekly pembrolizumab for 18 doses (adjuvant-only group). Event-free survival at two years was 72% in the neoadjuvant-adjuvant group compared with 49% in the adjuvant-only group. A similar number of patients in the neoadjuvant group did not proceed to the adjuvant therapy phase, as compared with patients randomized to adjuvant therapy who did not receive pembrolizumab after surgery. There was no increased toxicity from giving the first three cycles of pembrolizumab neoadjuvantly.

References

- 1 Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet* 2023;402:2197-2208. [https://doi.org/10.1016/S0140-6736\(23\)02033-0](https://doi.org/10.1016/S0140-6736(23)02033-0)
- 2 CADTH Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2024;4(7). <https://doi.org/10.51731/cjht.2024.930>
- 3 Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med* 2023;388(9):813-823. <https://doi.org/10.1056/NEJMoa2211437>
- 4 CADTH Reimbursement Recommendation. Pembrolizumab (Keytruda®) for the neoadjuvant-adjuvant treatment of adult patients with stage III or stage IV melanoma. 2024.

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

The **Calaspargase Pegol Monograph** has been developed with expert review provided by Dr. Jennifer Kendrick (clinical pharmacy specialist, BC Children's Hospital). **Calaspargase pegol** is a pegylated conjugate of L-asparaginase (*E. coli*-derived asparaginase), an enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia. Calaspargase pegol is used in the treatment of acute lymphoblastic leukemia. The usual dose in pediatric and adult patients is 2500 units/m² IV for one dose every three weeks.

Highlights from these documents include:

- calaspargase pegol can lead to fluctuation in clotting factors; risk of bleeding and/or clotting may be increased
- glucose intolerance is commonly reported; monitor for signs/symptoms of hyperglycemia throughout treatment
- calaspargase pegol should be avoided in patients with severe hepatic impairment

Calaspargase pegol has been added to the **Chemotherapy Preparation and Stability Chart**. Asparaginase was previously evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Monograph and Patient Handout are made available for reference only.

The **Capivasertib Monograph** and **Patient Handout** have been developed with expert review provided by Nathalie Levasseur (medical oncologist, BC Cancer Breast Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Capivasertib is an orally administered kinase inhibitor that targets all three isoforms of serine/threonine AKT (AKT1, AKT2 and AKT3). It is used in combination with fulvestrant in the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations. The usual dose is 400 mg orally twice daily for four consecutive days starting on day 1 of each week.

Highlights from these documents include:

- blood glucose should be optimized prior to starting treatment
- diarrhea occurs frequently and prompt initiation of loperamide is recommended
- serious cutaneous reactions such as erythema multiforme, palmar-plantar erythrodysesthesia and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported

Capivasertib has been added to the **Auxiliary Label List** and was evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Chemotherapy Preparation and Stability Chart entry is made available for reference only.

The **Datopotamab deruxtecan Interim Monograph** has been developed. Datopotamab deruxtecan is an antibody drug conjugate comprised of a TROP2 inhibiting IgG1 monoclonal antibody bound to a topoisomerase inhibitor via a cleavable linker. Datopotamab deruxtecan is currently being investigated for treatment of non-small cell lung cancer, small cell lung cancer, and breast cancer. The usual dose is 6 mg/kg IV given on day 1 of a three weekly cycle.

Highlights from this document includes:

- infusion-related reactions are reported; premedication with antihistamine, acetaminophen, +/- glucocorticoid is recommended prior to each dose
- keratitis is an identified risk of treatment; avoiding contact lenses while on treatment and regular use of artificial tears are recommended for prevention
- oral mucositis/stomatitis is common and can be severe; adherence to good oral hygiene and daily use of a steroid containing mouthwash are recommended for prevention

Datopotamab deruxtecan has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Carboplatin Monograph

Special Precautions: *Pregnancy* – updated duration of contraception

Side Effects table: updated emetogenic potential

Olaparib Monograph

Special Precautions: *Caution* – added statement regarding hematologic recovery
Carcinogenicity – updated timeline for emergence and citation

Side Effects table: updated emetogenic potential, side effect incidence, and added/deleted side effects per current product information

Side Effects paragraphs: updated *hematologic toxicities* (deleted information about hemorrhagic stroke as not causally related to drug); added new paragraph about *nausea/vomiting*

Thiotepa Monograph and Chemotherapy Preparation and Stability Chart

<i>Common Trade Name:</i>	added brand name for European product
<i>Pharmacokinetics table:</i>	updated all sections
<i>Uses:</i>	updated Health Canada-approved indications, and primary/other uses
<i>Special Precautions:</i>	added bullets; updated <i>Carcinogenicity, Fertility, and Pregnancy</i> ; deleted FDA Pregnancy category
<i>Side Effects table:</i>	added urinary symptoms
<i>Side Effects paragraphs:</i>	added new paragraphs for gastrointestinal toxicity, myelosuppression, neurotoxicity and skin excretion
<i>Supply and Storage:</i>	updated with Canadian marketed brands (Hikma, SteriMax); deleted SAP brand
<i>Solution Preparation and Compatibility:</i>	deleted preparation information (normally included in the Chemotherapy Preparation and Stability Chart); deleted compatibility information (no longer included in this section)
<i>Parenteral Administration table:</i>	deleted information that cannot be corroborated in current product information or other references; updated per current information
<i>Dosage Guidelines:</i>	added information pertaining to stem cell transplantation; updated dosage in myelosuppression, renal failure, and hepatic failure
<i>Chemotherapy Preparation and Stability Chart:</i>	added Canadian marketed brands (Hikma, SteriMax); deleted SAP brand

Trastuzumab Emtansine Monograph

<i>Side Effects table:</i>	updated messaging regarding extravasation hazard and injection site reactions
<i>Side Effects paragraphs:</i>	added new paragraph regarding extravasation

Chemotherapy Preparation and Stability Chart

<i>Doxorubicin pegylated liposomal:</i>	added US-labelled brand (Taro USA) approved by Health Canada for drug shortage (vials labelled with Sun Pharmaceuticals as manufacturer)
<i>Topotecan:</i>	added information regarding intrathecal route of administration to all current brands

Editorial Board Changes

The Cancer Drug Manual[©] Editorial Review Board would like to bid farewell to **Megan Crosby (Interim Director, Professional Practice Nursing, BC Cancer – Prince George)**. Thank you, Megan, for your years of contributions to the Cancer Drug Manual[©] board. We wish you all the best and hope that you will rejoin the board in the future. Replacing Megan while she is in her new role is **Stephanie Townsend (Clinical Nurse Educator, BC Cancer – Kelowna)**. Welcome Stephanie. We look forward to working with you.

Community Oncology Network

Terrace CON Clinic – New Facility, New Name

The CON site within **Terrace** has now moved to their new facility **Ksyen Regional Hospital** (formerly known as Mills Memorial Hospital). This name change is reflected in the CONRef program when selecting a CON site. Please update any local or regional documentation to reflect the new facility name for the Terrace CON clinic. Ksyen, pronounced as KUH-see-yen, comes from the Tsimshian Sm'algyax language name for the Skeena River.

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 December 2024:

Protocol Title	Protocol Code	Benefit Status
Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	GIGAVPCOXT	Class I
Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	GIGAVPFOXT	Class I
Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma using Pembrolizumab	SMNAPEM	Class I

Deleted Programs

The following programs have been deleted from the BC Cancer [Benefit Drug List](#) effective 01 December 2024:

Protocol Title	Protocol Code	Benefit Status
Topical Carmustine in Cutaneous T-Cell Lymphoma	LYCARTOP	Class I
Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab Vedotin	LYCTCLBV <i>(new patients to follow LYBRENTUX)</i>	Class I

List of New & Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol Title	Protocol	PPPO	Handout
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
GIGAVPFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
SMNAPEM	Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma using Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
CN Neuro-Oncology				
CNCARV	Carboplatin and Etoposide in the Treatment of Recurrent Ependymoma and Oligodendroglioma	<i>Tests and emetogenic risk category updated</i>	<i>Premedications and tests updated</i>	--
CNELTZRT	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	<i>Tests updated, minor formatting</i>	<i>Tests updated</i>	--
GI Gastrointestinal				
GIAAVCT	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	<i>Emetogenic risk category updated</i>	<i>Premedications updated</i>	--
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Tests updated</i>	--	--
GIRCRT	Combined Modality Adjuvant Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Eligibility clarified</i>	--	--
GO Gynecologic				
GOENDAVPL	Treatment of Endometrial Cancer with Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	<i>Formatting error corrected</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
HN Head and Neck				
HNLAALPRT	Summary for Locally Advanced (Alternate) Head and Neck Cancer using Cisplatin during Radiation Therapy	<i>Tests clarified</i>	--	--
HNLACETRT	Summary for Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	<i>Tests clarified</i>	--	--
HNLAPRT	Summary for Combined Chemotherapy Cisplatin and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	<i>Tests clarified</i>	--	--
HNNLAPRT	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation	<i>Tests clarified; dose modifications updated</i>	--	--
LY Lymphoma				
HLHETCSPA	Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and Cyclosporine	<i>Tests, supportive medications and precautions updated</i>	<i>Standing orders for etoposide toxicity removed; tests updated</i>	--
LYABVD	Treatment of Hodgkin Lymphoma with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine	<i>Dose modifications clarified</i>	<i>Standing orders for etoposide toxicity removed</i>	--
LYACAL	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	<i>Tests and supportive medications updated</i>	<i>Tests updated</i>	--
LYALEM	Treatment with Subcutaneous or Intravenous Alectuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alectuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYALIT	Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sézary Syndrome) with Alitretinoin	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
LYASPMEDX	Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma using Pegaspargase, Methotrexate and Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYAVDBV	Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	<i>Tests updated; dose modifications clarified</i>	<i>Tests updated; standing orders for etoposide toxicity removed</i>	--
LYBEND	Treatment of Non-Hodgkin Lymphoma with Bendamustine	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYCDA	Treatment of Hairy Cell Leukemia with Cladribine	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LYCHLOR	Therapy for Indolent Lymphoma and Chronic Lymphocytic Leukemia using Chlorambucil	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYCHOP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine and Prednisone (CHOP)	<i>Tests, supportive medications and precautions updated; dose modifications clarified</i>	<i>Standing orders for etoposide toxicity removed; tests updated</i>	--
LYCHOPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Tests updated; dose modifications clarified</i>	<i>Standing orders for etoposide toxicity banner removed; tests updated</i>	--
LYCHOPR	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (CHOP-R)	<i>Dose modifications clarified</i>	<i>Standing orders for etoposide toxicity banner removed</i>	--
LYCHOPRMTX	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma	<i>Dose modifications clarified</i>	<i>Standing orders for etoposide toxicity removed</i>	--
LYCHPBV	Treatment of CD30-Positive Peripheral T-Cell Lymphoma (PTCL) with Doxorubicin, Cyclophosphamide, Prednisone (CHP) and Brentuximab Vedotin	<i>Tests, supportive medications, and precautions updated; dose modifications clarified</i>	<i>Standing orders for etoposide toxicity removed; tests updated</i>	--
LYCLLBEND	Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) with Bendamustine	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYCSPA	Cyclosporine for Cytopenias Associated with Lymphoproliferative Disorder of Large Granular Lymphocytes	<i>Tests and precautions updated, supportive medications added</i>	<i>Tests updated</i>	--
LYCVP	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone (CVP)	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYCVPPABO	Treatment of Hodgkin Lymphoma with Cyclophosphamide, Vinblastine, Procarbazine, Prednisone, Doxorubicin, Vincristine and Bleomycin	<i>Tests, supportive medications, and precautions updated; dose modifications clarified</i>	<i>Standing orders for etoposide toxicity removed; tests updated</i>	--
LYCYCLO	Therapy of Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma using Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYDARCBDF	Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible-for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LYFACAL	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	<i>Tests and supportive medications updated</i>	<i>Tests updated</i>	--
LYFIBRU	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Ibrutinib	<i>Tests and supportive medications updated</i>	<i>Tests updated</i>	--
LYFLU	Treatment of Low-Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYGDP	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYGEMOXPEG	Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	<i>Tests, antiviral medications and precautions updated</i>	<i>Tests updated</i>	--
LYGVLD	Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	<i>Tests and precautions updated; supportive medications added</i>	<i>Tests updated</i>	--
LYHDMRTEM	Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYHDMTXPRO	Central Nervous System Prophylaxis with High-Dose Methotrexate in Diffuse Large B-Cell Lymphoma	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYIBRU	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Ibrutinib	<i>Tests and supportive medications updated</i>	<i>Tests updated</i>	--
LYIT	Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYIVACR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYMFBEX	Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sézary syndrome) with Bexarotene	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
LYMFECF	Treatment of Cutaneous T-Cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis	<i>Tests and precautions updated</i>	--	--
LYMIBRU	Treatment of Relapsed/Refractory Mantle-Cell Lymphoma using Ibrutinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LYNIV	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Nivolumab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYNIV4	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 4-Weekly Nivolumab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYPALL	Lymphoma Palliative Chemotherapy	<i>Tests section added; precautions updated</i>	--	--
LYPEM	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Pembrolizumab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYPEM6	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 6-Weekly Pembrolizumab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYPRA	Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Pralatrexate	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	--	<i>Standing orders for etoposide toxicity removed</i>	--
ULYROMI	Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Romidepsin	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LYSILTUX	Treatment of Multicentric Castleman's Disease (MCD) Negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV-8) using Siltuximab	<i>Tests, supportive medications and precautions updated</i>	<i>Pre-chemo metrics added; tests updated</i>	--
LYSMILE	Treatment of Natural Killer or T-Cell Lymphoma using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide	<i>Tests, antimicrobial prophylaxis and precautions updated</i>	<i>Labs updated; standing orders for etoposide toxicity removed</i>	--
LYVENOB	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	<i>Tests updated; contact pharmacist removed</i>	<i>If clinically indicated HBsAg removed</i>	--
LYVIPDRT	Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-Cell Lymphoma, using Concurrent Radiation and weekly Cisplatin Followed by Etoposide, Ifosfamide, Cisplatin and Dexamethasone	<i>Tests, antiviral prophylaxis and precautions updated</i>	<i>Tests updated; standing orders for etoposide toxicity removed</i>	--
MY Myeloma				
MYBLDF	Treatment of Previously Untreated Multiple Myeloma and Not-Eligible-for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
MYBLDPRE	Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYBORMTN	Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYBORPRE	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYBORREL	Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYBSD	Treatment of Multiple Myeloma using Bortezomib, Selinexor and Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYCARDEX	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYCARLD	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYDARBD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYDARCBDF	Treatment of Previously Untreated Multiple Myeloma and Not-Eligible-for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYDARLD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYDARLDF	Treatment of Previously Untreated Multiple Myeloma and Not-Eligible-for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYHDC	Single Dose Cyclophosphamide Priming Therapy for Multiple Myeloma Prior to Autologous Stem Cell Transplant	<i>Tests and precautions updated, supportive medications added</i>	--	--
UMYISACARD	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
UMYISAPOMD	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
UMYLDLF	Treatment of Previously Untreated Multiple Myeloma and Not-Eligible-for Stem Cell Transplant using Lenalidomide with Low-Dose Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYLDREL	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYLENMTN	Maintenance Therapy of Multiple Myeloma using Lenalidomide	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYMP	Treatment of Multiple Myeloma using Melphalan and Prednisone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
MYMPBOR	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
UMYPOMDEX	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated, pharmacy use area corrected to indicate pomalidomide</i>	--
PU Primary Unknown				
PUCAT	Treatment Primary Treatment of Cancer of Unknown Primary Origin using Carboplatin and Paclitaxel	<i>Antiemetic therapy post-chemotherapy section removed; emetogenic risk category added; contact pharmacist removed</i>	<i>Premedications updated</i>	--
SA Sarcoma				
SATEMBEV	Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma using Temozolomide and Bevacizumab	<i>Tests, precautions and references updated; temozolomide renal dose modifications removed</i>	<i>Prechemo metrics and tests updated</i>	--
SM Skin & Melanoma				
SMMCCAWE	A Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma using Avelumab	<i>Exclusions updated</i>	--	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@phsa.ca
Provincial Systemic Therapy Network	604-877-6000 x 672247	ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN